Expansion of Remote Patient Monitoring (RPM) and Telehealth
Expansion of remote patient monitoring (RPM) and telehealth presents a major opportunity for the global artificial intelligence (AI) market in diabetes management, especially as diabetes prevalence rises and healthcare systems seek scalable solutions to reach underserved populations. RPM leverages digital and connected devices to capture real-time patient data—including glucose levels, medication adherence, and lifestyle metrics—which is then transmitted to clinicians and analyzed remotely, often with AI support for trend detection and predictive alerts.
A 2025 program at the University of Colorado enrolled 211 patients with uncontrolled type 2 diabetes into an RPM initiative, replacing traditional in-person visits with digital coaching and medication oversight. Certified diabetes educators contacted patients every one to two weeks, while endocrinologists used AI-enabled RPM for real-time medication adjustments and treatment optimization. The program, called the Diabetes Home and Remote Care Program (DHRCP), enrolled 211 patients with uncontrolled Type 2 diabetes. An analysis of 106 patients (50.2% of participants) who completed the program showed an average HbA1c reduction from 10.4% to 7.0%.
Another multi-center study illustrated that RPM use among 1,928 newly diagnosed diabetes patients achieved higher rates of HbA1c improvement compared to conventional office-based monitoring, with 74% of RPM users achieving HbA1c targets versus 62% of non-users.
Telehealth models, particularly during the COVID-19 pandemic, accelerated RPM adoption globally; general RPM claims in Medicare beneficiaries increased by 555% from February 2020 to September 2021, while routine telehealth use for diabetes management reached 43% among U.S. adults.
AI-driven RPM and telehealth platforms enable continuous patient engagement, early detection of adverse events, and targeted interventions, reducing the need for frequent travel and improving population-level outcomes. As demographic shifts and chronic disease burdens intensify, RPM and telehealth will remain essential drivers for the global expansion of AI-driven diabetes management and care accessibility.
Emergence of Generative AI and Predictive Analytics
The emergence of generative AI and predictive analytics is generating substantial opportunity for the global artificial intelligence (AI) diabetes management market by enabling unprecedented levels of personalization, automation, and clinical insight. Generative AI models including variational autoencoders and transformers produce synthetic patient data, augment clinical datasets, and simulate glucose-insulin dynamics, countering data scarcity and variability challenges commonly encountered with real-world data. These models support accelerated algorithm development, robust scenario testing, and cohort expansion for training and validating AI-powered diabetes care solutions.
Predictive analytics leverages deep learning and advanced data modeling to forecast glycemic trends, complications, and therapeutic response. For instance, large studies have demonstrated that AI-driven predictive tools integrating continuous glucose monitoring (CGM), wearable sensor data, and lifestyle factors can accurately predict hypoglycemia, hyperglycemia, and long-term hemoglobin A1c outcomes, enabling proactive interventions. Advanced AI systems such as those based on transformer architecture like CGMfroster specialize in learning from large-scale CGM data, delivering precise predictions for postprandial responses and tailoring dietary advice and interventions. These predictive features empower clinicians to optimize insulin dosing and adjust therapy in real time, improving both efficacy and safety.
Generative language models now produce human-like patient education, simulate virtual health coaches, and facilitate scalable, evidence-based diabetes self-management support, addressing gaps in resource-limited environments. AI-augmented digital twins allow for “what-if” scenario analyses, optimizing care for individual patients with complex diabetes profiles. Collectively, these innovations are transforming diabetes management from reactive to anticipatory and personalized models, supporting improved outcomes and expanding equitable access to advanced care worldwide.
Partnerships Between Tech Giants and Healthcare Providers
Partnerships between tech giants and healthcare providers are creating significant opportunities for the global artificial intelligence (AI) market in diabetes management by combining technological innovation with clinical expertise. These collaborations enable the development and deployment of integrated AI-powered platforms that enhance diabetes care through improved glucose monitoring, insulin delivery, predictive analytics, and personalized patient management.
For example, In August 2024, Medtronic’s partnership with Abbott integrates Medtronic’s insulin pumps with Abbott's continuous glucose monitors (CGMs) like the FreeStyle Libre system to create more seamless, automated insulin delivery systems. Such closed-loop systems improve patient outcomes by maintaining tighter glucose control and reducing hypoglycemic events. Additionally, companies like Glytec have partnered extensively with hospitals and health systems, providing AI-driven insulin management software that guides clinicians in real-time dosing decisions. Glytec’s Glucommander platform is used in more than 400 hospitals and has demonstrated reductions in hypoglycemia and hospital length-of-stay, showcasing the clinical and operational value these partnerships can unlock.
Another example, In Aug 2023, Kakao Healthcare (the digital health arm of South Korean tech-giant Kakao Corporation ) entered into a strategic collaboration with Novo Nordisk to develop a smart health service for diabetes patients in South Korea, integrating mobile and AI technologies in a country where approximately six million adults (about one in six) live with diabetes.
Large tech firms like Google, Apple, and Amazon continue to collaborate with healthcare providers and diabetes-focused startups to integrate AI, cloud computing, and wearable technologies. For instance, Apple’s Health and ResearchKit platforms facilitate real-time diabetes data collection while supporting AI analytics to inform clinical care. These partnerships also emphasize interoperability, data security, and patient engagement key factors in scaling AI diabetes solutions globally.
Moreover, initiatives such as the RSSDI Diabetes Digital Health Grant in India, supported by partnerships with NASSCOM and medical societies, represent localized efforts to drive AI and digital innovation in diabetes care using collaborative models. Overall, these partnerships accelerate AI adoption, expand access to advanced diabetes management tools, and improve clinical outcomes through data-driven, personalized care.
Market Factor Analysis
Value chain analysis
The global market for AI in diabetes management is rapidly evolving, shaped by technological advancements, rising diabetes prevalence, demand for personalized care, and the increasing adoption of digital health solutions. The value chain for this market includes seven core components: Data Generation & Acquisition, Data Processing & Storage, AI Model Development, Integration with Devices & Platforms, Clinical Validation & Regulatory Approval, Deployment & Commercialization, and Patient Engagement & Feedback, with continuous feedback loop into Model Optimization.
Data Generation & Acquisition
The first stage in the AI value chain for diabetes management revolves around the generation and acquisition of diverse, high-quality health data. This data is collected from multiple sources, including continuous glucose monitors (CGMs), insulin pumps, smart glucometers, wearable fitness devices, electronic health records (EHRs), lab reports, and p
